Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 18/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.52 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18138831 | 0.92 | HCRTR2 (0.51) | HCRTR2HCRTR1 | |
| SCHEMBL18138786 | 0.92 | HCRTR2 (0.54) | HCRTR2HCRTR1 | |
| SCHEMBL18138799 | 0.90 | HCRTR2 (0.64) | HCRTR2HCRTR1 | |
| SCHEMBL18138850 | 0.89 | PFKFB3 (0.57) | HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL18138824 | 0.89 | HCRTR2 (0.54) | HCRTR2HCRTR1 | |
| SCHEMBL18138744 | 0.86 | HCRTR2 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL18138808 | 0.84 | HCRTR2 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL18138792 | 0.84 | HCRTR2 (0.46) | HCRTR2HCRTR1DNMT3BALDH1A1 | |
| SCHEMBL18138783 | 0.83 | HCRTR2 (0.64) | HCRTR2HCRTR1 | |
| SCHEMBL18138791 | 0.81 | DNMT3B (0.44) | HCRTR2DNMT3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081553-B1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIV TSUKUBA (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-9815787-B2 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2017-11-14 | — | — | US | disclosed |
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2016-12-15 | — | — | US | disclosed |
| EP-3081553-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2016-10-19 | — | — | EP | disclosed |
| CN-106029633-A | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | 国立大学法人筑波大学 | 2016-10-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | HCRTR2 1/4885HCRTR1 2/4885DNMT3B 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.